In this discussion, Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a health economics study that was recently published.
Higher clinical benefit rate with front-line cabazitaxel versus androgen receptor inhibitor
A playwright with male breast cancer examines some beliefs that may influence our survival.
Matthew Smith, MD, PhD, Harvard Medical School, shares his thoughts on the importance of bone health in the prostate cancer patient population.
Combination trial missed response endpoint but exceeded historical results